These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers. Evans WE; Relling MV Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245 [TBL] [Abstract][Full Text] [Related]
4. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Smith CA; Gough AC; Leigh PN; Summers BA; Harding AE; Maraganore DM; Sturman SG; Schapira AH; Williams AC Lancet; 1992 Jun; 339(8806):1375-7. PubMed ID: 1350805 [TBL] [Abstract][Full Text] [Related]
5. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Dawson E; Powell JF; Nöthen MM; Crocq MA; Lanczik M; Körner J; Rietschel M; van Os J; Wright P; Gill M Psychiatr Genet; 1994; 4(4):215-8. PubMed ID: 7712118 [TBL] [Abstract][Full Text] [Related]
6. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Pelkonen O; Vainio H Pharmacogenetics; 1993 Feb; 3(1):19-27. PubMed ID: 8097947 [TBL] [Abstract][Full Text] [Related]
7. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Ford GA; Wood SM; Daly AK Br J Clin Pharmacol; 2000 Jul; 50(1):77-80. PubMed ID: 10886124 [TBL] [Abstract][Full Text] [Related]
8. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242 [TBL] [Abstract][Full Text] [Related]
11. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238 [TBL] [Abstract][Full Text] [Related]
12. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Douglas AM; Atchison BA; Somogyi AA; Drummer OH Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695 [No Abstract] [Full Text] [Related]
13. Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls. Sugimura H; Caporaso NE; Shaw GL; Modali RV; Gonzalez FJ; Hoover RN; Resau JH; Trump BF; Weston A; Harris CC Carcinogenesis; 1990 Sep; 11(9):1527-30. PubMed ID: 1976046 [TBL] [Abstract][Full Text] [Related]
15. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268 [TBL] [Abstract][Full Text] [Related]
16. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity. Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590 [TBL] [Abstract][Full Text] [Related]